C81.4A
Lymphocyte-rich Hodgkin lymphoma, in remission
Clinical Classification Guidelines
Medical Intelligence & Overview
Lymphocyte-rich Hodgkin lymphoma is a subtype of Hodgkin lymphoma characterized by a high number of lymphocytes, a type of white blood cell, within the affected tissues. When this condition goes into remission, it means that signs and symptoms of the disease have significantly decreased or disappeared, often after treatment. This status is a positive sign, indicating that the disease is under control, although ongoing monitoring is typically necessary to ensure it does not return.
Causes & Symptoms
Clinical Causes: Genetic factors that may increase susceptibility Previous exposure to certain viruses, such as Epstein-Barr virus (EBV) Immune system dysfunction or suppression Environmental exposures, though specific triggers remain unclear Family history of lymphomas or related cancers
Key Symptoms: Swollen lymph nodes, often painless Persistent fatigue or weakness Fever that comes and goes Night sweats Unexplained weight loss Itching or skin rash Unexplained pain or pressure in affected areas
Diagnostic & Treatment
Diagnosis Path: Diagnosing lymphocyte-rich Hodgkin lymphoma involves several steps. Initially, a thorough physical examination is performed to assess lymph node swelling and other symptoms. Imaging tests such as X-rays, CT scans, or PET scans are used to identify the extent of affected areas. A definitive diagnosis requires a tissue biopsy, where a sample of lymph node tissue is examined under a microscope for characteristic Reed-Sternberg cells. Additional blood tests may help evaluate overall health. After treatment, ongoing assessments are conducted to confirm remission and monitor for potential relapse.
Treatment Protocols: Treatment options for lymphocyte-rich Hodgkin lymphoma typically include chemotherapy, radiation therapy, or a combination of both. The specific regimen depends on factors such as disease stage, patient health, and response to initial treatment. Chemotherapy involves the use of medications to destroy cancer cells, while radiation therapy uses high-energy beams to target affected tissues. In some cases, targeted therapies or immunotherapies might be considered. Following successful treatment, patients are usually monitored regularly, as remission can sometimes be followed by relapse, which may require additional therapies.
Clinical Advice & FAQs
Billing Guidance
Is C81.4A a billable ICD-10 code?
Yes, C81.4A is a specific, billable code that can be used to indicate a diagnosis for reimbursement purposes.
Documentation
How do I report C81.4A?
Clinical documentation must specify the nature of Lymphocyte-rich Hodgkin lymphoma, in remission and any associated comorbidities for accurate reporting.
Cite this Clinical Reference